VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 200 filers reported holding VAXCYTE INC in Q4 2022. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,710,453 | +6.3% | 896,635 | +4.1% | 0.01% | +12.5% |
| Q2 2023 | $42,995,393 | +71.7% | 860,941 | +28.8% | 0.01% | +60.0% |
| Q1 2023 | $25,047,959 | -20.8% | 668,302 | +1.4% | 0.01% | -28.6% |
| Q4 2022 | $31,614,921 | +172.2% | 659,331 | +36.3% | 0.01% | +133.3% |
| Q3 2022 | $11,613,000 | +14.9% | 483,892 | +4.2% | 0.00% | +50.0% |
| Q2 2022 | $10,104,000 | +9.5% | 464,337 | +21.5% | 0.00% | 0.0% |
| Q1 2022 | $9,228,000 | +4.4% | 382,125 | +2.9% | 0.00% | +100.0% |
| Q4 2021 | $8,838,000 | -7.1% | 371,462 | -1.0% | 0.00% | -50.0% |
| Q3 2021 | $9,517,000 | +15.6% | 375,107 | +2.6% | 0.00% | +100.0% |
| Q2 2021 | $8,230,000 | +43.2% | 365,652 | +25.7% | 0.00% | 0.0% |
| Q1 2021 | $5,746,000 | -3.1% | 290,958 | +30.4% | 0.00% | 0.0% |
| Q4 2020 | $5,929,000 | -44.0% | 223,120 | +4.0% | 0.00% | -50.0% |
| Q3 2020 | $10,593,000 | – | 214,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $100,049,000 | 34.21% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $45,299,000 | 18.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 776,039 | $18,625,000 | 6.81% |
| Kynam Capital Management, LP | 698,638 | $16,767,000 | 3.53% |
| GREAT POINT PARTNERS LLC | 600,000 | $14,400,000 | 3.47% |
| Frazier Life Sciences Management, L.P. | 1,547,405 | $37,138,000 | 2.86% |
| Ghost Tree Capital, LLC | 360,000 | $8,640,000 | 2.42% |
| RA Capital Management | 4,581,203 | $109,949,000 | 2.35% |
| Opaleye Management Inc. | 190,000 | $4,560,000 | 1.88% |
| TPG GP A, LLC | 3,285,504 | $78,852,000 | 1.29% |